Awardee OrganizationUNIVERSITY OF MIAMI SCHOOL OF MEDICINE
Description
Abstract Text
Amyloid-bodies and the Evolution of Malignancies
Project Summary
The ability of cancer cells to adapt to a wide variety of stress conditions plays a critical role in various
physiological facets of tumorigenesis. We recently reported the discovery of stress-induced low complexity
noncoding RNA derived from stimuli-specific loci of the ribosomal intergenic spacer (rIGSRNA); an enigmatic
region of the human genome historically dismissed as “junk” DNA. We showed that low complexity rIGSRNA
activate a physiological amyloidogenic program that converts nucleoli into Amyloid-bodies: reversible nuclear
membrane-less compartments composed of immobilized proteins in an amyloid-like state. While many cellular
bodies have been described as liquid-like (e.g., stress granules, P-bodies, germ cell granules), the discovery of
Amyloid-bodies provided evidence of an amyloidogenic program that can physiologically transition biological
matter to a solid state. Amyloid-bodies are found in sub-populations of cells in normal tissues, the core of low-
grade human tumors and cells responding to various stimuli highlighting their ubiquitous nature. Proteomic
analysis revealed that Amyloid-bodies immobilize participants of the DNA synthesis machinery and cell cycle
control, amongst many other metabolic regulators. Intriguingly, Amyloid-bodies share many biophysical
properties with the amyloidogenic, solid-like Balbiani-bodies involved in metabolic suppression in Xenopus.
Likewise, yeast solidify elements of their proteome to sporulate and arrest growth in non-permissive conditions.
This raises the fascinating possibility that stressed cancer cells assemble Amyloid-bodies to enter a spore-like
state of extreme metabolic depression. In this grant proposal, we will show preliminary data that low complexity
rIGSRNA coordinate unusual RNA tailing programs to drive system-wide amyloidogenic phase transition. This
post-translational pathway enables cancer cells to immobilize elements of the DNA synthesis machinery and halt
oncogenic signaling in an adaptive response to severe environmental insults. Based on these preliminary and
published results, we hypothesize that “Nucleolar phase transition programs temporarily suspend oncogenicity”.
We plan to test this hypothesis by: 1- Uncovering mechanisms of physiological phase transition; 2- Examining
how low complexity rIGSRNA activate RNA tailing programs; 3- Demonstrating a role for RNA tailing-mediated
phase transition in tumorigenesis. The discovery of dedicated enzymatic programs that drive physiological
amyloidogenesis provides a unique opportunity to study the role of liquid-to-solid phase transition in human
clinical samples and in vivo tumor assays. By studying clinical samples, in culture and orthotopic animal models,
we will test if phase transition induces a unique and yet uncharacterized cancer cell state of extreme metabolic
depression, while highlighting biochemical functions for low complexity RNA typically discarded as useless
nucleic acids.
Public Health Relevance Statement
Amyloid-bodies and the Evolution of Malignancies
Narrative
Cancer cells encounter various adverse environmental conditions during tumorigenesis. Our group has recently
discovered that cancer cells solidify their proteins to enter spore-like state, like how yeast undergo sporulation.
By this process of protein solidification, cancer cells can resist the harsh conditions of the tumor
microenvironment.
No Sub Projects information available for 1R01CA275828-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01CA275828-01A1
Patents
No Patents information available for 1R01CA275828-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01CA275828-01A1
Clinical Studies
No Clinical Studies information available for 1R01CA275828-01A1
News and More
Related News Releases
No news release information available for 1R01CA275828-01A1
History
No Historical information available for 1R01CA275828-01A1
Similar Projects
No Similar Projects information available for 1R01CA275828-01A1